Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Systemic infection with Neisseria meningitidis leads to a devastating, septicaemic illness with a high mortality, particularly in children. Currently, there are no vaccines to prevent disease caused by strains of N. meningitidis serogroup B, the commonest isolate in developed countries. Here, we describe the identification of vaccine candidates that protect mice against lethal challenge with this bacterium. A total 11 meningococcal proteins that are necessary for establishing systemic infection were expressed as recombinant antigens and assessed for their ability to protect animals against live bacterial challenge; the lactate permease (LctP) and ExbB, which is required for iron acquisition, elicited protective immunity. Both LctP and ExbB are expressed by a wide range of pathogenic isolates of N. meningitidis. Targeting bacterial factors required for pathogenesis may lead to new vaccines to protect individuals from this important human pathogen.

Original publication




Journal article



Publication Date





4136 - 4141


Bacterial Proteins, Humans, Meningococcal Infections, Meningococcal Vaccines, Neisseria meningitidis, Vaccines, Synthetic